Astellas Pharma Inc. (TYO:4503)
Japan
· Delayed Price · Currency is JPY | Market Cap | 2.62T |
| Revenue (ttm) | 1.87T |
| Net Income (ttm) | -57.43B |
| Shares Out | 1.79B |
| EPS (ttm) | -32.07 |
| PE Ratio | n/a |
| Forward PE | 20.75 |
| Dividend | 74.00 (5.05%) |
| Ex-Dividend Date | Mar 28, 2025 |
| Volume | 3,289,500 |
| Average Volume | 6,498,550 |
| Open | 1,458.50 |
| Previous Close | 1,453.50 |
| Day's Range | 1,458.50 - 1,474.00 |
| 52-Week Range | 1,415.00 - 1,835.00 |
| Beta | 0.23 |
| RSI | 44.59 |
| Earnings Date | Jan 31, 2025 |
About Astellas Pharma
Astellas Pharma Inc. manufactures, markets, and imports and exports pharmaceuticals in Japan and internationally. The company provides XTANDI, a treatment for prostate cancer; XOSPATA, a treatment for patients who have relapsed or refractory acute myeloid leukemia with a FLT3 mutation; and PADCEV, a treatment for patients with metastatic urothelial cancer. It also offers Evrenzo, a treatment for anemia associated with chronic kidney disease; Betanis/Myrabetriq/BETMIGA, a treatment for overactive bladder; and Prograf and Advagraf/Graceptor/ASTAG... [Read more]
Financial Performance
In 2023, Astellas Pharma's revenue was 1.60 trillion, an increase of 5.60% compared to the previous year's 1.52 trillion. Earnings were 17.05 billion, a decrease of -82.73%.
Financial StatementsNews
U.S. FDA Approves Expanded Label for Astellas' IZERVAY™ (avacincaptad pegol intravitreal solution) for Geographic Atrophy
IZERVAY dosing approved beyond 12 months TOKYO , Feb. 12, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced the U.S. Food and Drug Ad...
Pfizer/Astellas Tout Encouraging Data From Keytruda Combo Regime In Urothelial Cancer Showing 49% Reduction In Death Risk Vs. Chemo
On Monday, Pfizer Inc. (NYSE: PFE) and Astellas Pharma Inc. (OTC: ALPMF) (OTC: ALPMY) released additional follow-up results from the Phase 3 EV-302 trial (also known as KEYNOTE-A39) of Padcev (enfo...
Pfizer and Astellas' PADCEV® (enfortumab vedotin-ejfv) plus KEYTRUDA® (pembrolizumab) Shows Long-Term Efficacy in First-Line Treatment of Locally Advanced or Metastatic Urothelial Cancer (la/mUC)
Enfortumab vedotin plus pembrolizumab continues to demonstrate superior efficacy versus chemotherapy in a broad population, reinforcing the combination as standard of care in first-line treatment of l...
Astellas Pharma Inc. (ALPMF) Q3 2024 Earnings Call Transcript
Astellas Pharma Inc. 2024 Q3 - Results - Earnings Call Presentation
The following slide deck was published by Astellas Pharma Inc.
Astellas Submits New Drug Application for Conditional Approval of Avacincaptad Pegol for Geographic Atrophy in Japan
- Ministry of Health, Labour and Welfare to evaluate ACP as potential first and only treatment for patients with geographic atrophy (GA) secondary to age-related macular degeneration (AMD) in Japan - ...
Astellas Pharma Non-GAAP EPS of ¥124.60, revenue of ¥1453.03B; updates FY outlook
Astellas Makes Announcement about Management Structure
TOKYO , Feb. 4, 2025 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") today announced that the following changes to its management structure effective Apr...
ORYZON to Reshape Its Board of Directors at the Upcoming Shareholders' Meeting
Aimed at enhancing U.S. outreach, investor relations, corporate dialogue, and business development (BD) capabilities MADRID and CAMBRIDGE, Mass., Jan. 27, 2025 (GLOBE NEWSWIRE) -- Oryzon Genomics, S.A...
Pharma Giant Warns Pills Critical For Organ Transplant Patients' to Survive May Be Completely Empty in Urgent Recall
Pharmaceutical company Astellas Pharma announced two urgent recalls for vital immunosuppressive drugs, Prograf and Astagraf XL, that are used to prevent organ rejection in transplant recipients.
Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders
TOKYO--(BUSINESS WIRE)-- #Astellas--Axcelead DDP Enters into Drug Discovery Service Agreement with Astellas for Targeted Protein Degraders.
Sangamo spikes on Astellas licensing deal for gene therapy tech
Sangamo Therapeutics (SGMO) stock rises as the company announces a licensing agreement with Astellas Pharma (ALPMF) for gene therapy technology. Read more here.
Astellas and Dr. Jen Ashton launch "Cooler Moments" to Spotlight Menopausal Hot Flashes and Empower Women to Advocate for Themselves
"Cooler Moments" educates and empowers women in midlife to speak up for themselves and celebrate this natural change in their lives. NORTHBROOK, Ill.
Astellas Announces Desert Oasis Healthcare as First Health System to Implement DIGITIVA™ for Heart Failure Management
SAN FRANCISCO , Nov. 20, 2024 /PRNewswire/ -- Astellas Pharma U.S., Inc. (President: Mike Petroutsas, "Astellas") today announced that it has entered into an agreement with Desert Oasis Healthcare (DO...
Astellas Pharma Inc. (ALPMF) Q2 2024 Earnings Call Transcript
Astellas Pharma Inc. (OTCPK:ALPMF) Q2 2024 Earnings Call Transcript October 30, 2024 2:30 AM ETCompany ParticipantsHiromitsu Ikeda - Chief Communications...
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas: Can The Gastric Cancer Approval Be The Inflection Point?
Astellas Pharma reports H1 results
Astellas wins FDA nod for first-line gastric cancer therapy
Astellas Pharma's antibody drug Vyloy approved by the FDA with chemotherapy for first-line treatment of gastric or GEJ adenocarcinoma in certain adults. Read more here.
Astellas' VYLOY™ (zolbetuximab-clzb) Approved by U.S. FDA for Treatment of Advanced Gastric and GEJ Cancer
VYLOY is the first and only CLDN18.2-targeted treatment approved in the U.S. for adults with advanced gastric and gastroesophageal junction cancer whose tumors are CLDN18.2 positive TOKYO , Oct. 18, 2...
FDA approves Astellas' gastric cancer therapy
The U.S. Food and Drug Administration approved Astellas' gastric cancer therapy, the health regulator's website showed on Friday.
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
TOKYO , Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura , "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate t...
Astellas to Present VEOZA™ (fezolinetant) Data at IMS World Congress on Menopause
TOKYO , Oct. 10, 2024 /PRNewswire/ -- Astellas Pharma Inc. (TSE: 4503, President and CEO: Naoki Okamura, "Astellas") announced that VEOZA™ (fezolinetant)*, its first-in-class treatment for moderate to...
Astellas and AviadoBio Announce Exclusive Option and License Agreement for Gene Therapy AVB-101 Targeting Frontotemporal Dementia and Other Indications
Astellas receives an exclusive option to license AVB-101, an investigational, AAV-based gene therapy in Phase 1/2 development AviadoBio receives $20 million equity investment, up to $30 million in up...
eyma Bahi appointed as head of Astellas Pharma Turkey, Middle East and Africa area
In her new role, she will oversee operations across 12 markets
Singlera Genomics and Astellas Present Methylation-based Organ Toxicity Detection at 2024 JSOT Annual Meeting
SAN DIEGO--(BUSINESS WIRE)--Singlera Genomics and Astellas Pharma presented results during the JSOT 2024 Annual Meeting demonstrating that drug-induced testicular toxicity can be detected using cell-f...